 | Vol. 11.14 – 13 April, 2022 |
| |
|
|
| Scientists used a “two cell type” whole genome CRISPR-Cas9 screening system to discover key regulators of tumor sensitivity and resistance to natural killer cell-mediated cytotoxicity in human glioblastoma stem cells. [Nature Communications] |
|  |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported that Rab13, a small GTPase, was highly expressed in breast CSCs. Rab13 depletion suppressed breast cancer cell stemness, tumorigenesis, and chemoresistance by reducing tumor-stroma crosstalk. [Cancer Research] |
|
|
|
| Scientists showed that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 in glioma stem cells drove immunosuppression in glioblastoma. [Cancer Immunology Research] |
|
|
|
| Researchers defined mesenchymal and stem-like prostate cancer, traced its origin to therapy-induced lineage plasticity, and revealed its sensitivity to HER2/3 inhibition. [Cell Reports] |
|
|
|
| Scientists assessed that a subset of glioblastoma multiforme stem-like cells from high-grade gliomas was self-sufficient in the activation of regulatory growth signaling. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Investigators explored the effect of sinomenine hydrochloride (SH) on breast cancer stem cells (BCSCs) and its mechanism and observed that SH decreased the ratio of CD44+/CD24– BCSCs and the expression of BCSCs-related genes in MCF-7 and MDA-MB-231 cells. [Pharmacological Research] |
|
|
|
| The authors demonstrated that induction of a CD24-positive population is one mechanism by which IDH-mutant tumors acquired stem-like properties. [Neoplasia] |
|
|
|
| TGF-β from tumor-associated macrophages activated RAD18 in triple-negative breast cancer to enhance tumor stemness, forming a positive feedback loop. Inhibition of YAP or TGF-β broke this loop and suppressed cancer stemness and proliferation. [Cell Death Discovery] |
|
|
|
| Researchers established patient derived glioblastoma stem cells (GSCs), determined CSC marker expression, and immunostained GSCs to assess cell viability and apoptosis. [Stem Cells and Development] |
|
|
|
| The combined chemotherapy with methionine restriction could enhance the chemotherapeutic sensitivity of colorectal cancer stem cells by up-regulation of miR-320d to inhibit c-Myc expression. [Molecular and Cellular Biochemistry] |
|
|
|
| Investigators suggested that in the route to cisplatin chemoresistance, epigenetic modifications could be associated with epithelial-mesenchymal transition activation and cancer stem cell accumulation which originated more aggressive tumors. [Oral Diseases] |
|
|
|
|
| The authors summarize the role of immune cells providing CSCs to evade tumor immunity, and then discuss the intrinsic mechanisms represented by CSCs to promote tumors’ resistance to immunotherapies. [Stem Cell Research & Therapy] |
|
|
|
|
| SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset. [SELLAS Life Sciences Group, Inc.] |
|
|
|
| BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced that the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer. [BriaCell Therapeutics Corp.] |
|
|
|
|
| May 3 – 5, 2022 Berlin, Germany |
|
|
|
|
|
| Cyprus Cancer Research Institute – Nicosia, Cyprus |
|
|
|
| The University of Hong Kong – Hong Kong, China |
|
|
|
| Luxembourg Institute of Health – Strassen, Luxembourg |
|
|
|
| CRUK Manchester Institute – Manchester, United Kingdom |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
|